RecruitingPhase 2NCT06329401

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Avalyn Pharma Inc.
Principal Investigator: Avalyn Pharma, Inc.
Avalyn Pharma Inc.
Intervention: AP01(drug)
Enrollment: 375 target
Eligibility: 18 years · All sexes
Timeline: 2024 – 2027

Study locations (30)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States
University of Southern California, Los Angeles, California, United States
Cedars-Sinai, Los Angeles, California, United States
UCLA, Los Angeles, California, United States
Newport Native MD, Inc., Newport Beach, California, United States
Paradigm Clinical Research - Redding, Redding, California, United States
University of California - San Francisco, San Francisco, California, United States
University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States
National Jewish Health, Denver, Colorado, United States
UCONN Health, Farmington, Connecticut, United States
Yale University, New Haven, Connecticut, United States
Clinical Site Partners, LCC, Leesburg, Florida, United States
Renstar Medical Research, Ocala, Florida, United States
Clinical Site Partners, Winter Park, Florida, United States
+15 more locations on ClinicalTrials.gov

Collaborators

DevPro Biopharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06329401 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials